Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesInfectious DiseaseUTMB Correctional SSTI Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentUniversity of Texas Medical Branch Correctional Managed CarePolicy B-14.16

    Skin and Soft Tissue Infection

    Customize your policy alerts

    Sign up for universityoftexasmedicalboard Policy B-14.16 alerts

    Get alerted when Policy B-14.16 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Standardizes clinical management, education, infection-control measures, and housing-related care for inmates with skin and soft tissue infections, particularly MRSA and MSSA, under correctional healthcare.

    Policy Summary
    PayerUniversity of Texas Medical Branch Correctional Managed Care
    PolicySkin and Soft Tissue Infection
    Policy CodePolicy B-14.16
    Change TypeNo material change
    Effective DateAug 27, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionFor non-purulent infection, use empiric therapy primarily covering streptococci and reassess response within 48–72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    48–72 hoursReassessment interval for non-purulent infection without improvement
    72 hoursMinimum oral antibiotic period before considering escalation
    5 daysMinimum antibiotic duration generally recommended
    >3 in 6 monthsRecurrent infection threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Do not use
    Rifampin monotherapy

    Clinical Management and Coverage Criteria

    Higher-Level Care Evaluation

    Evaluate the inmate for higher-level care when either of the following clinical conditions is present. The listed findings are not exhaustive; use clinical judgment.

    ANY of the following

    • Concerning signs or symptoms suggestive of systemic infection.
    • Signs of a potentially severe or critical skin or soft tissue infection (SSTI).

    Escalation After Failed Oral Antibiotics

    Consider escalation of antibiotics and referral to a higher level of care when both conditions are present.

    ALL of the following

    • The inmate has received at least 72 hours of oral antibiotics.
    • The infection has not responded or has worsened.

      Consider parenteral antibiotics, broader coverage, or other escalation as clinically appropriate.

    Abscesses and Draining Lesions

    Manage abscesses and other draining skin lesions according to systemic findings, lesion characteristics, size, recurrence, trauma, and underlying conditions.

    ALL of the following

    • Promptly identify the abscess or draining lesion and refer the inmate to the facility physician or mid-level practitioner.
    • Assess for signs and symptoms of systemic disease.
    • If concerning findings are present

      • Refer for infirmary or inpatient management when there are concerning signs or symptoms suggestive of systemic infection.
      • Refer for infirmary or inpatient management when there are signs of a potentially severe or critical SSTI.
    • If there are no systemic signs or symptoms, no underlying chronic illness likely to compromise immunity, and the lesion is not recurrent

    Culture During Higher-Level-Care Referral

    When referring an inmate to a facility for higher-level care, consider obtaining an SSTI culture using the Levine method. Do not delay or deprioritize immediate transfer for culture collection.

    Levine-method culture procedure

    • Clean and irrigate the wound with sterile or normal saline to remove slough, necrotic tissue, or dried exudate.
    • Prepare the sterile swab

      • If the wound is moist, use a sterile swab directly from the package.
      • If the wound is dry, moisten the swab tip with sterile water.
    • Swab the wound base in a zig-zag motion over viable tissue in the center for 5 seconds, applying sufficient pressure to express fluid from within the wound tissue.

    Acute Infection Management

    Manage an acute skin or soft tissue infection according to lesion fluctuation and suspected source.

    ALL of the following

    • Address the lesion

      • Perform I&D if the lesion is fluctuant.
      • If the lesion is not yet fluctuant, treat with warm compresses for 20 minutes at a time, 2–3 times per day.
    • Prescribe antibiotics.
    • If the infection is due to an animal or human bite and oral antibiotics are appropriate, consider amoxicillin and clavulanate.

    Recurrent Infection Evaluation and Management

    When recurrent staphylococcal SSTI is identified, evaluate for recurrence-related causes, immunocompromising conditions, and appropriate follow-up.

    Recurrent staphylococcal SSTI

    • The inmate has more than 3 culture-proven staphylococcal infections in a 6-month period.> 3 infections in 6 months
    • Obtain C&S using aseptic technique.
    • Search for local causes of recurrent abscesses, including pilonidal cyst, hidradenitis suppurativa, or foreign material.
    • Evaluate for immunocompromising conditions.
    • Perform evaluation as indicated, which may include history and physical examination, urine glucose, fasting blood sugar, HIV testing, and referral to specialty clinics.

    Decolonization and Follow-Up

    Consider decolonization for inmates with recurrent abscesses or recurrent cultured MRSA infection who may benefit. Explain that success is low and recolonization may occur.

    Consider decolonization when ANY of the following applies

    • The inmate has recurrent abscesses and may benefit from decolonization.
    • The inmate has a recurrent infection with cultured MRSA.

    Moderate Infection Assessment

    For a moderate skin infection, consider obtaining blood cultures if any one of the following findings is identified.

    ANY of the following

    • Systemic signs of infection.
    • An immunocompromising condition defined in this policy.
    • Extensive or rapidly progressing erythema.

    Antibiotic Treatment

    When antibiotic treatment is indicated for suspected MSSA or MRSA, use empiric therapy as appropriate and refine treatment when culture results are available.

    ALL of the following

    • Antibiotic treatment is indicated for suspected MSSA or MRSA.
    • Provide empiric therapy when clinically appropriate, but whenever possible guide antibiotic therapy by C&S results once available.
    • Refer to the Skin and Soft Tissue Infection DMG for antibiotic options based on infection severity.
    • Treat for a duration based on clinical judgment, generally at least 5 days; extend therapy if the infection has not improved within that time.

    Contact Precautions

    Manage the inmate under contact precautions when the infection condition and at least one qualifying risk condition are present.

    ALL of the following

    • The inmate has an active purulent MRSA infection or another multidrug-resistant bacterial infection.
    • At least ONE of the following

      • The inmate is being treated in a medical setting, such as an infirmary or dialysis unit.
      • The inmate is unwilling or unable to understand follow-up management, or is nonadherent with antibiotic treatment or therapy.
      • The inmate has a large abscess or draining skin lesion that cannot be adequately covered and kept dry and clean, such as a scalp lesion or decubitus lesion.

    Discontinuation of Special Housing

    Special housing may be discontinued when either qualifying condition is met.

    ANY of the following

    • The lesion is clinically resolved.
    • ALL of the following

      • There is no longer cellulitis, lymphangitis, or drainage from an open lesion, such as a decubitus lesion.
      • The inmate has completed at least 72 hours of the antibiotic course.

    Do not give rifampin as monotherapy.

    Clinical Thresholds and Treatment Parameters

    Abscess lesion size
    Less than 5 cmA fluctuant lesion with redness and swelling less than 5 cm across may be treated with incision and drainage alone.
    5 cm or moreA fluctuant lesion measuring 5 cm or more across requires culture and sensitivity before incision and drainage, with antibiotics prescribed.
    Measurement basisMeasure the area of redness and swelling across the lesion.
    Response reassessment interval
    Reassessment intervalReassess response within 48–72 hours.
    No improvementIf the infection does not improve within 48–72 hours, switch to another agent with reliable streptococcal coverage.

    Required Provider Actions

    Prior Authorization

    Obtain approval for intranasal mupirocin

    Obtain nonformulary approval before applying mupirocin 2% intranasally for a positive MRSA nares culture. When approved, apply it generously inside both nostrils with a cotton swab twice daily for 5 days in the medical department.

    Prior Authorization

    Obtain approval for repeat decolonization

    Nonformulary approval is required when repeating mupirocin 2% and providing topical chlorhexidine 4% solution for recurrent cultured MRSA infection. Each treatment is provided for 5 days.

    Step Therapy

    Use streptococcal coverage and reassess

    For a non-purulent infection, use empiric therapy that primarily provides streptococcal coverage. If there is no improvement within 48–72 hours, switch to another agent with reliable streptococcal coverage and consider consultation with a Pharmacy Clinical Practice Specialist.

    Disease Background

    Staphylococcus aureus may colonize the nasopharynx, skin, or clothing without causing active disease and can spread through direct interpersonal contact. When trauma or dermatologic disease breaches skin or mucosal integrity, the organism may enter underlying tissue and produce lesions such as abscesses. This policy addresses MRSA and MSSA treatment, prevention of antimicrobial resistance, and measures to reduce transmission.

    Definitions

    Staphylococcus aureus
    PathogenStaphylococcus aureus is a major human pathogen.
    Disease potentialIt can colonize and infect hospitalized inmates with decreased host defenses and healthy immunologically competent people.
    Transmission and lesionsIt may be carried in the nasopharynx, on the skin, or on clothing; direct contact can transfer it, and breached skin or mucosa can permit abscess formation.
    Colonization
    DefinitionColonization means Staphylococcus aureus is present without signs of active disease.
    Common sitesThe organism may be carried in the nasopharynx, on the skin, or on clothing.
    Policy Summary
    PayerUniversity of Texas Medical Branch Correctional Managed Care
    PolicySkin and Soft Tissue Infection
    Policy CodePolicy B-14.16
    Change TypeNo material change
    Effective DateAug 27, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionFor non-purulent infection, use empiric therapy primarily covering streptococci and reassess response within 48–72 hours.
    SourceLink
    On This Page
    Clinical Management and Coverage CriteriaClinical Thresholds and Treatment ParametersRequired Provider ActionsDisease BackgroundDefinitions
    • Manage according to fluctuant status and lesion size

      • If the lesion is not yet fluctuant, treat with warm compresses for 20 minutes at a time, 2–3 times per day.
      • If the lesion is fluctuant and the area of redness and swelling is less than 5 cm across, treat with incision and drainage (I&D) alone.
      • If the lesion is 5 cm or more across, obtain culture and sensitivity (C&S), perform I&D, and prescribe antibiotics.
  1. Assess for trauma, including animal or human bites, and for underlying immunosuppressive conditions.
  2. When trauma or an underlying immunosuppressive condition is present

    • Obtain a culture using the Levine method.
    • Perform I&D if the lesion is fluctuant; if it is not yet fluctuant, use warm compresses for 20 minutes at a time, 2–3 times per day.
    • Prescribe antibiotics.
    • For an animal or human bite when oral antibiotics are appropriate, consider amoxicillin and clavulanate.
  3. Send the specimen for Gram stain and culture.
  4. Control any underlying condition as well as possible.
  5. The inmate is immunocompromised or has cellulitis, lymphangitis, or sepsis as a complication.
  6. The inmate meets the definition of recurrent staphylococcal SSTI, meaning more than 3 infections in a 6-month period.> 3 infections in 6 months
  7. The inmate has failed decolonization procedures twice.
  8. ConsultationConsider consultation with a Pharmacy Clinical Practice Specialist when changing therapy.
    Warm-compress treatment
    DurationApply warm compresses for 20 minutes at a time.
    FrequencyUse warm compresses 2 to 3 times per day.
    IndicationUse this regimen when the lesion is not yet fluctuant.
    Recurrent staphylococcal skin and soft tissue infection
    Frequency thresholdMore than 3 staphylococcal skin or soft tissue infections in a six-month period.
    Culture-proven definitionFor the culture-proven definition, the infections must be culture-proven.
    Clinical significanceThis frequency meets the policy definition of recurrent staphylococcal skin and soft tissue infection.
    Antibiotic duration before special-housing discontinuation
    Minimum durationAt least 72 hours of the antibiotic course must be completed.
    Required clinical statusCellulitis, lymphangitis, and drainage from an open lesion must no longer be present.
    Housing decisionThese findings support discontinuation of special housing when the lesion is not otherwise clinically resolved.
    Documentation Required

    Consider culture during higher-level referral

    When referring an inmate to a facility for a higher level of care, consider obtaining a culture from the skin and soft tissue infection site using the Levine method. Culture collection must not delay sending the inmate out for immediate care.

    Documentation Required

    Document severity and risk factors

    Assess and document systemic signs or symptoms, potentially severe or critical skin and soft tissue infection, chronic illness that may compromise immunity, recurrence, trauma such as bites, and underlying immunosuppressive conditions. Concerning findings may require infirmary, inpatient, or higher-level care.

    Documentation Required

    Perform and document Levine-method culture

    When culture is indicated, obtain the specimen using the Levine method and document the collection. Clean and irrigate the wound, use a sterile swab or moisten it with sterile water if the wound is dry, swab viable wound tissue in a zig-zag motion for 5 seconds with sufficient pressure, and send it for Gram stain and culture.

    Documentation Required

    Obtain culture and sensitivity

    For recurrent infection, obtain culture and sensitivity using aseptic technique to guide evaluation and management.

    Documentation Required

    Culture the nares for MRSA

    Culture the external nares and identify the laboratory specimen as being cultured for MRSA.

    Documentation Required

    Monitor recurrence

    Monitor for subsequent infection and continue to follow the inmate and the incidence and frequency of skin and soft tissue infections. If concerned about the frequency of infections, reach out to an Infectious Disease Specialist.

    Documentation Required

    Document obesity counseling and diet offer

    For obese inmates, counsel on weight reduction, ensure that the diet has been considered for health, and document that the counseling and diet were offered.

    Documentation Required

    Document lesion status and treatment adherence

    Document whether the lesion can be adequately covered while remaining dry on its surface and whether the inmate is adherent to the treatment regimen. Also document whether cellulitis, lymphangitis, or drainage from an open lesion has resolved when determining housing or discontinuing special precautions.

    Billing Rule

    Report MSSA and MRSA within seven days

    Report methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) to the Office of Public Health within seven days of receipt on the unit by email or fax.

    • Submit Attachment B, the Staph Aureus Surveillance Reporting Form.
    • Include a copy of the laboratory report.
    Note

    Provide disposal for contaminated materials

    When dressing changes are performed in the infirmary or by inmates, provide for appropriate disposal of contaminated materials.

    Transmission potential
    Colonized individuals can transmit Staphylococcus aureus to others through direct interpersonal contact.
    Methicillin-resistant Staphylococcus aureus (MRSA)
    Acquisition categoriesMRSA is usually categorized as hospital-acquired or community-acquired.
    Correctional settingIn the Texas Department of Criminal Justice setting, MRSA most closely resembles community-acquired MRSA.
    SusceptibilityThe MRSA in this setting remains susceptible to many other antibiotics.
    Immunocompromising conditions
    Metabolic and infectious conditionsDiabetes, HIV, end-stage renal disease, and end-stage liver disease or cirrhosis are included.
    MalignancyActive malignancy receiving chemotherapy is included.
    Immunocompromising medicationsLong-term steroid therapy, biologic agents, post-transplant immunosuppression, and other agents that may cause immunocompromise are included.
    Severe or critical skin and soft tissue infection
    Prosthetic or vascular involvementInvolvement of a vascular graft or prosthetic joint qualifies.
    Necrotizing and tissue-threatening conditionsGas gangrene, necrotizing infection, sausage digit, Fournier's gangrene, and compartment syndrome qualify.
    Toxic shock syndromeToxic shock syndrome qualifies as a severe or critical skin and soft tissue infection.
    Systemic symptoms of infection
    TemperatureTemperature greater than 100.4°F or less than 96.8°F.
    Respiratory rateRespiratory rate greater than 24 breaths per minute.
    Heart rateHeart rate greater than 90 beats per minute.
    White blood cell countWhite blood cell count greater than 12,000 or less than 400 cells/µL.
    Other systemic findingsAltered mental status or hemodynamic instability also qualifies.
    Recurrent staphylococcal skin or soft tissue infection
    Frequency thresholdMore than 3 staphylococcal skin or soft tissue infections in a six-month period.
    Culture requirementThe infections must be culture-proven.
    Assessment useThis definition is used to determine whether a staphylococcal infection is recurrent.
    Recurrent staphylococcal skin and soft tissue infection
    Frequency thresholdMore than 3 infections in a six-month period.
    Organism contextThe definition applies to recurrent staphylococcal skin and soft tissue infection.
    Contact-precaution relevanceMeeting this definition is one listed risk condition for contact precautions when the infection condition is present.
    Contact precautions
    Infection conditionContact precautions apply for an active purulent MRSA infection or another multidrug-resistant bacterial infection.
    Risk-condition requirementAt least one specified risk condition must also be present.
    Examples of risk conditionsListed risks include immunocompromise, nonadherence, a large inadequately covered or uncleanable abscess or draining lesion, cellulitis, lymphangitis, sepsis, recurrent staphylococcal infection, or two failed decolonization procedures.
    MSSA
    AbbreviationMSSA means methicillin-sensitive Staphylococcus aureus.
    OrganismMSSA is Staphylococcus aureus that is methicillin-sensitive.
    ReportingMSSA must be reported to the Office of Public Health within seven days of receipt on the unit.